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ABSTRACT
AIMS AND BACKGROUND: To evaluate toxicity and the radical resection rate in gastric adenocarci-
noma treated with preoperative neoadjuvant chemoradiation.
MATERIALS & METHODS: 32 patients, 22 males and 10 females with gastric adenocarcinoma, were 
treated with chemoradiation and hyperthermia.
RESULTS: The neoadjuvant regimen was completed as planned in 19/32 (59 %) patients; in the re-
maining patients the intensity of chemotherapy had to be reduced because of haematological and 
gastrointestinal toxicity. Surgical stage was as follows: 2 patients pathologically complete response, 3 
patients AJCC stage I.A, 5 patients stage I.B, 7 patients stage II, 7 patients stage III.A, 1 patient stage 
III.B, 7 patients stage IV. R0 resection was achieved in 19/32 (59%) patients, R1 in 2/32 (6%) patients 
and R2 in 11 (34%) patients. Downstaging after neoadjuvant chemoradiotherapy was achieved in 
17/32 (53%) patients. At the date of evaluation (31 March 2009), 4 patients were still alive 58, 81, 86 
and 98 months from the date of diagnosis. Median survival was 18 months (95% confi dence interval: 
13–38 months). One-year survival was 69% (95% confi dence interval: 53%–85%). Four-year survival 
was 19% (95% C.I.: 5%–34%).
CONCLUSIONS: Preoperative neoadjuvant chemoradiotherapy has acceptable toxicity, and can lead to 
a high rate of R0 resections.
KEY WORDS: gastric cancer, preoperative neoadjuvant chemoradiotherapy, hyperthermia
Received: 2.10.2009
Accepted: 2.10.2009
Subject: original article
1Department of Oncology 
and Radiotherapy, 
Charles University Medical School 
and Teaching Hospital, 
Czech Republic
2Department of Surgery, 
Charles University Medical School 
and Teaching Hospital,
 Czech Republic
3Department of Pathology, 
Charles University Medical School 
and Teaching Hospital, 
Czech Republic
4Department of Oncology, 
Palacky University Medical School 
and Teaching Hospital, 
Czech Republic
Address for correspondence:
Josef Dvorak
Department of Oncology and 
Radiotherapy
Charles University Medical School 
& Teaching Hospital
Hradec Králové
50005
Czech Republic
Tel.: +420-495833708
Fax: +420-495832081
e-mail: dvorakj@fnhk.cz
Acknowledgement: 
Supported by research project 
MZO 00179906.
BACKGROUND
The mainstay of curative treatment of locally 
advanced gastric adenocarcinoma is radical 
surgery. Complete surgical tumour removal 
with microscopically negative margins (R0 
resection) is of fundamental importance for 
the patient's prognosis. Locoregional relapse 
is a major problem after curative surgery in 
gastric adenocarcinoma.
Preoperative neoadjuvant chemoradiother-
apy has been widely used in the treatment of 
locally advanced oesophageal and rectal ad-
enocarcinoma, but studies in gastric adeno-
carcinoma are limited.
Unsatisfactory results of surgery alone in 
locally advanced gastric adenocarcinoma have 
led to an increased interest in adjuvant or neo-
adjuvant therapeutic approaches. According to 
a meta-analysis published by Hu in 2002, intra-
venous adjuvant chemotherapy after gastrecto-
my may have a positive effect on the outcome 
in gastric cancer [1]. However, the evidence is 
not strong because of the generally low meth-
odological quality of most of the randomized 
trials of adjuvant chemotherapy. The princi-
pal aim of neoadjuvant therapy is to enable the 
surgeon to achieve radical resection with mi-
croscopically negative margins (R0 resection). 
Preoperative radiotherapy in gastric cancer 
has been tested in several non-randomized [2, 
3, 4, 5] and randomized studies [6, 7, 8].
AIM
The aim of the present retrospective analysis 
was to evaluate toxicities and the rate of radi-
cal resection with microscopically negative 
margins (R0 resection) in gastric adenocarci-
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noma treated according to a protocol of preop-
erative neoadjuvant chemoradiation.
MATERIALS & METHODS
Patients
Between March 1999 and December 2003, 
32 patients, 22 males and 10 females, median 
age 63 (range 28–80) years, with gastric ad-
enocarcinoma were treated with neoadjuvant 
chemoradiation at the Department of Oncol-
ogy and Radiotherapy, Charles University 
Medical School Teaching Hospital in Hradec 
Králové. Initial examinations included case 
history, physical examination, blood count, 
biochemistry, lung X-rays, abdominal US, 
gastroscopy, spiral abdominal contrast CT, 
endosonography, and endobiopsy. Staging was 
based on AJCC classifi cation [9]. All patients 
had histology of adenocarcinoma: 1 patient 
grade 1, 10 patients grade 2, 17 patients grade 
3 and 4 patients grade 4. Pre-treatment stage 
was as follows: 1 patient AJCC stage I.B, 12 
patients stage II, 15 patients stage III.A and 4 
patients stage IV. 
Anatomical localization of the tumour was 
as follows: cardia 8 patients, body 6 patients, 
antrum 5 patients, pylorus 1 patient, lesser 
curvature 4 patients and greater curvature 8 
patients. The median of pre-treatment haemo-
globin level was 131 (range 92–163) g/l, leuco-
cytes 7.4 (range 3.2–11.6) 109/l and thrombo-
cytes 260 (range 122–438) 109/l.
Toxicity was evaluated according to the 
Common Toxicity Criteria for Adverse Events 
version 3.0.
Treatment
The following regimens of chemoradiation 
were used: two 3-week cycles of 5-fl uoroura-
cil (5-FU) 200 mg/m2 continuously days 1–21 
with calcium folinate 45 mg per day, cispla-
tin 25 mg/m2 days 1, 8, 15, paclitaxel 60 mg/
m2 days 1, 8, 15 and concomitant radiotherapy 
30 Gy in 15 fractions (2 Gy daily) of stomach 
and regional nodes (10 patients; completed in 
5/10 patients), in 6/10 patients combined with 
ultrasound hyperthermia once weekly during 
the second cycle of chemotherapy (completed 
in 2/6 patients); 5-FU 200 mg/m2 continuously 
4 weeks and cisplatin 25 mg/m2 days 1, 8, 15, 
22, paclitaxel 60 mg/m2 days 1, 8, 15, 22 and 
concomitant radiotherapy 40 Gy in 20 frac-
tions (2 Gy daily) of stomach and regional 
nodes (5 patients; completed in 1/5 patients), 
in 2/5 patients combined with ultrasound hy-
perthermia once weekly (completed in all pa-
tients); 5-FU 200 mg/m2 continuously 3 weeks 
and cisplatin 25 mg/m2 days 1, 8, 15 and con-
comitant radiotherapy 30 Gy in 15 fractions 
(2 Gy daily) of stomach and regional nodes (7 
patients; completed in 5/7 patients); 5-FU 200 
mg/m2 continuously 4 weeks and cisplatin 25 
mg/m2 days 1, 8, 15, 22 and concomitant radio-
therapy 40 Gy in 20 fractions (2 Gy daily) of 
stomach and regional nodes (3 patients; com-
pleted in all patients); 5-FU 200 mg/m2 contin-
uously 4 weeks and concomitant radiotherapy 
40 Gy in 20 fractions (2 Gy daily) of stomach 
and regional nodes (7 patients; competed in 
5/7 patients). Surgery was performed within 
5 weeks after completion of chemoradiother-
apy. It consisted of gastrectomy with lymph-
adenectomy. Histological examination of the 
resected tissue with lymphatic block and sur-
rounding lymph nodes was performed.
Radiation therapy
External beam radiation was administered 
concomitantly with the second cycle of che-
motherapy.
Radiotherapy with two conformal radia-
tion fi elds, anterior-posterior and posterior-
anterior, involved the entire stomach with 
perigastric extension and major lymph nodes 
at risk. Fields were individually modifi ed as it 
was necessary to spare as much normal tissue 
as possible, and to shield at least one wholly 
functional kidney in summation. Function of 
kidneys was initially evaluated by dynamic 
scintigraphy. The scheduled dose of radiation 
was delivered by a linear accelerator (Clinac 
600 or Clinac 2100, Varian Medical Systems, 
Palo Alto, CA, U.S.A.) using 6-MV or 15-MV 
photons. Radiotherapy was delivered 5 days 
per week and covered every radiation fi eld. A 
total dose of 30 Gy in 15 fractions was planned 
in 17 patients (in 1 of 17 patients the dose had to 
be reduced because of the haematological and 
gastrointestinal toxicity of chemoradiotherapy) 
and 40 Gy in 20 fractions in 15 patients (in 4 of 
15 patients the dose had to be reduced because 
of the haematological and gastrointestinal tox-
icity of chemoradiotherapy).
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Hyperthermia
Hyperthermia was performed using the 
Sonotherm 1000 Ultrasound Therapy System 
(Labthermics Technologies, Champaign, IL, 
U.S.A.) The temperature in the target volume 
was 41 ºC to 43 ºC for 45 minutes. Tissue up 
to a depth of 10 cm was heated by an ultra-
sound frequency of 1 MHz. Temperature was 
measured by 2 thermometric probes. Hyper-
thermia was applied during the chemoradio-
therapy once weekly after administration of 
cisplatin and paclitaxel and after radiothera-
py. Hyperthermia was planned in 8 patients 
(in 4/8 it had to be reduced because of the 
haematological and gastrointestinal toxicity 
of chemoradiotherapy).
Statistical analysis
Overall survival was analyzed using the Ka-
plan-Meier method.
RESULTS
Of the 32 patients treated with neoadjuvant 
chemoradiation, R0 resection was achieved 
in 19/32 (59%) patients, R1 (microscopic re-
sidual tumour) in 2/32 (6%) patients and R2 
(macroscopic residual tumour) in 11 (34%) pa-
tients. Surgical stage was as follows: 2 patients 
pathologically complete response, 3 patients 
AJCC stage I.A, 5 patients stage I.B, 7 patients 
stage II, 7 patients stage III.A, 1 patient stage 
III.B, 7 patients stage IV. Downstaging after 
neoadjuvant chemoradiotherapy was achieved 
in 17/32 (53%) patients. At the date of evalu-
ation (31 March 2009), 4 patients were still 
alive 58, 81, 86 and 98 months from the date of 
diagnosis. The median survival was 18 months 
(95% confi dence interval (C.I.): 13–38 months) 
[Graph]. One-year survival was 69% (95% C.I.: 
53%–85%), two-year survival 50% (95% C.I.: 
33%–67%), three-year survival 38% (95% C.I.: 
21%–54%) and four-year survival 19% (95% 
C.I.: 5%–34%). In multivariate analysis, only 
low grade was an independent indicator of bet-
ter prognosis (hazard ratio 0.14, 95% C.I. 0.03–
0.63, p = 0.01). Among 19 patients 12 patients 
had a recurrence after R0 resection, includ-
ing 3 patients with abdominal carcinomatosis, 
1 patient with abdominal carcinomatosis and 
liver metastases, 2 patients with liver metas-
tases, 3 patients with retroperitoneal lymph 
node metastases, 2 patients with lung metas-
tases and 1 patient with local recurrence and 
left ovarian metastasis.
Treatment compliance and toxicity
Preoperative neoadjuvant chemoradiotherapy 
was relatively well tolerated in most patients, 
and there was no treatment-related mortality. 
Most adverse events were mild to moderate in 
intensity, and all of them recovered spontane-
ously with supportive management. Grade 3–4 
leucopenia occurred in 4/32 (13%) patients, 
grade 3–4 thrombocytopenia in 2/32 (6%) pa-
tients, grade 3 anaemia in 2/32 patients (6%), 
and nausea, vomiting and diarrhoea grade 3 
in 5/32 (16%) patients. The median nadir of 
haemoglobin was 115 (range 65–147) g/l, leu-
cocytes 2.95 (range 0.6–6.3) 109/l and throm-
bocytes 154 (range 18–259) 109/l. One patient 
suffered myocardial infarction 28 days after 
completion of neoadjuvant chemoradiation. 
The neoadjuvant regimen was completed as 
planned in 19/32 (59%) patients, but in the re-
maining patients the intensity of chemother-
apy had to be reduced because of haemato-
logical and gastrointestinal toxicity. 4/8 (50%) 
patients did not complete potentiation with 
hyperthermia and 5/32 (16%) patients did not 
complete radiotherapy. In 16/32 patients pleu-
ral adhesion was observed in the region of the 
left costophrenic angle on the chest X-ray. In 
4 patients this was observed on the baseline 
staging chest X-ray before the start of neo-
adjuvant chemoradiotherapy, in 2 patients 
in the period after the start of neoadjuvant 
chemoradiotherapy before surgery and in 10 
patients after surgery. In 1 patient pleural ad-
hesion was observed in the region of the right 
costophrenic angle after surgery. Neoadjuvant 
chemoradiotherapy did not increase surgical 
mortality. We did not observe hand-foot syn-
drome in this series of patients. There was no 
treatment-related death.
DISCUSSION
Present retrospective data indicate the use of 
neoadjuvant chemoradiation in patients with 
gastric carcinoma. As expected, tumour grade 
was an independent prognostic factor in the 
present cohort. No other independent prognos-
tic indicators were identifi ed, but the size of 
the cohort was rather limited for multivariate 
analysis.
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In Western countries, the majority of pa-
tients diagnosed with gastric carcinoma have 
locally advanced disease [10]. A curative 
resection can be performed in about half of 
these patients, but even after an R0 resection 
two thirds of the patients will present with re-
currence within 2–3 years [10, 11].
The advantage of preoperative radiothera-
py, compared with postoperative radiothera-
py, is that the target volume is much easier to 
delineate because the tumour is still in situ. 
Moreover, tumour downsizing may facilitate 
surgery [12]. Pathological evaluation of re-
sponse to therapy adds prognostic information 
[13]. The neoadjuvant approach allows assess-
ment of pathological response in the treated 
tumour. The obvious disadvantage is that pre-
treatment pathological staging is absent [12].
Two randomized trials of adjuvant radio-
therapy versus surgery alone were performed 
[10, 14, 15]. Both trials concluded that there 
is no evidence of benefi t for adjuvant radio-
therapy alone in gastric cancer [10, 14, 15]. A 
three-arm randomized trial, performed by the 
British Stomach Cancer Group, compared ad-
juvant chemotherapy, adjuvant radiotherapy 
and surgery alone [14]. The fi ve-year survival 
for surgery and adjuvant chemotherapy was 
19%, for surgery and adjuvant radiotherapy 
12% and surgery alone 20% [14]. In a ran-
domized trial in 115 patients with resectable 
gastric carcinoma patients received adjuvant 
intraoperative radiotherapy or surgery alone 
[15]. There was no evidence of a benefi t for 
adjuvant intraoperative radiotherapy [15].
A prospective randomized Chinese trial in 
370 patients compared surgery with preopera-
tive radiotherapy of 40 Gy and surgery alone [6]. 
The fi ve-year and ten-year survival of the preop-
erative and surgery group and the surgery alone 
group were 30% and 20%, 20% and 13%, respec-
tively [6]. Resection rates (90% versus 79%) and 
radical resection rates (80% versus 61%) also in-
creased after preoperative radiotherapy [6].
In a randomized trial of intensive preop-
erative radiotherapy with local hyperthermia 
for the treatment of gastric carcinoma 293 
patients were randomized into 3 treatment 
groups: surgery alone, surgery with preopera-
tive radiotherapy (20 Gy in 4 fractions) and 
surgery with preoperative radiotherapy (20 
Gy in 4 fractions) and hyperthermia [7]. Pre-
operative radiotherapy did not improve 3- or 
5-year survival in gastric cancer patients in 
comparison with surgery alone [7]. Preopera-
tive radiotherapy in combination with local 
hyperthermia signifi cantly improved three-
year and fi ve-year survival [7]. In unresect-
able gastric adenocarcinoma patients, radio-
therapy and radiotherapy with hyperthermia 
both increased mean survival [7].
In a Russian trial, 152 patients were ran-
domized between surgery with preoperative 
radiotherapy (20 Gy in 5 fractions) and sur-
gery alone [8]. The fi ve-year survival of the 
preoperative and surgery group and the sur-
gery alone group were 39% and 30%, respec-
tively, which was not statistically different [8]. 
The same authors performed a prospective 
clinical trial of preoperative radiotherapy (20 
Gy in 5 fractions) in combination with a ra-
diosensitizer (metronidazole). Of 91 patients 
who received preoperative radiotherapy, 67 
patients were operated on with curative intent 
and were eligible for further analysis. Acute 
gastrointestinal toxicity was signifi cant, but 
manageable without delaying surgery in most 
cases. There were 4 postoperative deaths. The 
fi ve-year and ten-year survival was 46% and 
36%, respectively [5].
In a phase I-II study of neoadjuvant ra-
diochemotherapy for locally advanced gastric 
cancer 19 patients were enrolled and 18 com-
pleted neoadjuvant therapy [4]. Patients re-
ceived 2 cycles of cisplatin on day 1, 5-fl uorou-
racil (5-FU) on days 1 to 4 and leucovorin on 
days 1 to 4 every 3 weeks, concomitantly with 
radiotherapy escalated in 3 dose tiers (31.2, 
38.4 and 45.6 Gy) [4]. Pathological assessment 
showed 1 complete and 8 partial responses [4]. 
Two-year and three-year survival rates were 
71% and 59%, respectively [4]. Only 1 patient 
relapsed locally, and the peritoneum was the 
most frequent site of relapse [4].
In a pilot study, 24 patients were treated 
with preoperative external beam radiotherapy 
(45 Gy) with concurrent 5-FU given as a con-
tinuous infusion [16]. Surgical resection and 
intraoperative radiotherapy to a dose of 10 Gy 
followed 4–6 weeks after chemoradiotherapy 
[16]. A pathologically complete response was 
observed in 2 (11%) of the resected patients 
and 12 (63%) had pathological evidence of a 
signifi cant treatment effect [16].
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Thirty-four patients were enrolled in a multi-
institutional trial of preoperative chemoradio-
therapy in patients with potentially resectable 
gastric carcinoma [2]. Patients received up to 
two 28-day cycles of induction chemotherapy 
of 5-FU, leucovorin, and cisplatin, followed by 
45 Gy of radiation plus concurrent 5-FU [2]. 
Twenty-eight (85%) of 33 patients underwent 
surgery [2]. The R0 resection rate was 70% 
and the pathologically complete response was 
30% [2]. A pathologically partial response was 
observed in 8 patients (24%) [2]. The median 
survival time for 33 patients was 33.7 months 
[2]. Patients achieving a pathologically com-
plete response or pathologically partial re-
sponse had a signifi cantly longer median sur-
vival time (64 months) than those achieving a 
less than pathologically partial response (13 
months) [2]. There were 2 treatment-related 
deaths [2].
In the study of paclitaxel-based chemoradia-
tion in localized gastric carcinoma 41 patients 
received two 28-day cycles of induction che-
motherapy of 5-FU, paclitaxel, and cisplatin 
followed by 45 Gy of radiation and concurrent 
fl uorouracil plus paclitaxel [3]. Pathological re-
sponse and R0 resection were correlated with 
overall survival and disease-free survival [3].
Forty patients (98%) underwent surgery, 
and 78% had an R0 resection [3]. There was a 
pathologically complete response of 20% and a 
pathologically partial response of 15% [3].
The Southwest Oncology Group (SWOG)/
Intergroup 0116 trial in 556 patients demon-
strated that combined chemoradiation follow-
ing complete gastric resection improves me-
dian time to relapse (30 versus 19 months) and 
overall survival (36 versus 27 months) [17]. 
Acute toxicity grade 3 was observed in 41% 
and grade 4 in 32% [17]. Three patients (1%) 
died from the toxic effects of the chemoradio-
therapy [17].
Several phase II studies of combination 
regimens of paclitaxel plus cisplatin or pacli-
taxel plus 5-FU for the treatment of advanced 
gastric cancer patients yielded response rates 
of 22%–65% and median survival times of ap-
proximately 10 months (range 6–14 months) 
[18, 19, 20, 21]. Although the studies differed 
with respect to drug regimen and population 
treated, the regimens were generally well 
tolerated, with myelosuppression as the most 
common toxicity [22]. At our department pa-
clitaxel was added in 16 patients.
With the addition of concomitant chemother-
apy to radiotherapy, acute toxicity, specifi cal-
ly myelosuppression, increases signifi cantly. 
The risk of myelosuppression increases with 
increasing number of chemotherapy agents or 
with increasing dose intensity.
It has been demonstrated in a meta-analy-
sis of tumours of other primary locations that 
continuous intravenous infusion of 5-FU is su-
perior to 5-fl uorouracil bolus in terms of tu-
mour response, and achieves a slight increase 
in overall survival [23]. Similarly, haemato-
logical toxicity was low in the present cohort 
of patients. Haematological toxicity is much 
less important in patients who receive 5-FU as 
a continuous intravenous infusion, but hand-
foot syndrome is more frequent in this group 
of patients [23]. We did not observe hand-foot 
syndrome in the present cohort of patients.
Concomitant chemoradiation has several ad-
vantages in comparison with both approaches 
used separately. A synergistic effect within the 
irradiated volume can be achieved and chemo-
therapy can affect micrometastases outside 
the irradiated fi elds. Chemoradiation has been 
successful in other gastrointestinal tumours, 
such as rectal, anal, oesophageal and pancre-
atic cancers and also in the palliative therapy 
of gastric cancer.
In our study on preoperative chemoradiation, 
we used a combination of continuous 5-FU, cis-
platin and paclitaxel. Paclitaxel and concurrent 
application of radiotherapy in patients with in-
operable gastric cancer demonstrated substan-
tial locoregional activity [24]. The haematologi-
cal and gastrointestinal toxicity was lower than 
reported in the literature [17]. A relatively low 
dose of radiation was selected because of the 
fear of complications, but a favourable safety 
profi le may allow for an increase of the dose up 
to 40 Gy in the future.
CONCLUSION
Neoadjuvant concomitant chemoradiotherapy 
for locally advanced gastric adenocarcinoma 
based on application of 5-FU, cisplatin, and 
paclitaxel, with radiotherapy at a dose of 
30–40 Gy is well tolerated and leads to a high 
percentage of pathological tumour responses 
and resections with microscopically negative 
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margins. In part of the presented cohort of 
patients we later retrospectively investigated 
the expression of epidermal growth factor re-
ceptor (EGFR), p53, p21 and p16 [25, 26].
We conclude that preoperative neoadjuvant 
chemoradiation using the schedules outlined 
above is relatively well tolerated, has accept-
able toxicity, can lead to a high rate of R0 re-
sections, does not seem to increase the opera-
tive risk, and might increase the locoregional 
control of the disease. An optimal regimen 
has to be identifi ed in future studies.
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